From its roots at King’s College London, MedPharm has grown into a global topical and transdermal CDMO with facilities in Guildford, UK and Durham, North Carolina.
Providing services from API to clinical batch supply, MedPharm is well-established as the global expert in dermatological, respiratory, ophthalmic, ungual, mucosal, and transdermal product development.
Clients from all over the globe have been successful using formulation development programs that are based on our pillars of scientific integrity, innovation, and rigor. The vast formulation and product development experience, offered by MedPharm’s experts, has contributed to the development and approval of 85 marketed products for clients around the globe, including the US, Europe and Japan.
MedPharm mitigates development risks, creating data packages more likely to attract investors and support submissions that inspire regulators’ confidence. We leverage our 25 years of industry experience to provide innovative and trusted guidance to clients, helping to secure their return on investment.
Pioneering research is fundamental to what we do here at MedPharm. With highly automated processes and proprietary technology, we are changing how our industry looks at topical formulation development.
This approach to projects means that we are constantly looking for opportunities to develop new formulation and drug delivery technologies. These proprietary tools, such as MedSpray®, enhance clients’ products, provide clinical benefits for patients and meet the increasingly stringent requirements of regulatory authorities.
MedPharm was the first company to achieve European approval of topical generic products as a biowaiver with in vitro testing only.
Proprietary performance testing models allows MedPharm to enhance the clinical efficacy of our clients’ compounds.
